Abstract：
:Prostate adenocarcinoma can manifest as a fairly indolent tumor or as a very aggressive cancer with significant invasive and metastatic potential. Common metastatic sites include bone, liver, lymph nodes, and adrenal glands. Dermatologic manifestations are rare. We present a case of a man who presented with breast skin changes that mimicked inflammatory breast carcinoma with specialized testing ultimately giving a diagnosis of metastatic prostatic adenocarcinoma. A 78-year-old man presented with left breast redness and swelling. Examination revealed an erythematous rash with subcutaneous edema over the left hemithoracic area. A breast ultrasound showed no focal mass, and a breast core biopsy had no evidence of tumor. A skin biopsy showed metastatic carcinoma in dermal lymphatics, and the tumor was found to have no estrogen or progesterone receptors or HER2 expression. Computed tomography scans, positron emission tomography, and a nuclear bone scan revealed widespread skeletal metastases. The patient received a 3-month course of capecitabine and cyclophosphamide with no improvement in his skin lesions. Subsequent immunohistochemical staining on the tumor specimen was positive for prostate-specific antigen (PSA) and alpha-methyl-CoA-racemase, confirming a diagnosis of metastatic prostatic adenocarcinoma. He received leuprolide and bicalutamide and demonstrated significant improvement with near-complete resolution of his skin lesions and a decrease in his PSA level. Prostatic adenocarcinoma presenting initially as a breast malignancy is a rarely recognizable clinical event. Undoubtedly, increased awareness and recognition of the rare entity described herein will allow for the prompt initiation of specific therapies, which might be of benefit to many patients.
journal_name
Clin Breast Cancerjournal_title
Clinical breast cancerauthors
Njiaju UO,Truica CIdoi
10.3816/CBC.2010.n.013subject
Has Abstractpub_date
2010-02-01 00:00:00pages
E3-5issue
1eissn
1526-8209issn
1938-0666pii
S1526-8209(11)70014-3journal_volume
10pub_type
杂志文章abstract：BACKGROUND:Patients with breast cancer with pathologic N3 (pN3) lymph node status have been proven to have a poor prognosis. This study aimed to establish a nomogram to predict overall survival (OS) in patients with pN3 breast cancer. MATERIALS AND METHODS:The eligible patients from the Surveillance, Epidemiology, and...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2020.06.002
更新日期：2020-12-01 00:00:00
abstract：PURPOSE:HER2 gene amplification and overexpression is associated with aggressive breast cancer and poor prognosis. Accurate HER2 testing of patients with breast cancer before treatment is important to ensure that as many patients with HER2-positive breast cancer as possible receive the most appropriate treatment and th...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/CBC.2007.n.040
更新日期：2007-10-01 00:00:00
abstract：BACKGROUND:Breast cancer metastases to an ipsilateral supraclavicular lymph node is assigned a N3 status in the TNM system and thus classified as stage III disease in the American Joint Commission on Cancer staging manual. Breast cancer metastatic to contralateral axillary lymph node (CAM) without metastases to any oth...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2017.10.019
更新日期：2018-08-01 00:00:00
abstract：:Acellular dermal matrix has revolutionized implant-based breast reconstruction. Breast reconstruction has evolved from the traditional submuscular to the new prepectoral implant based (also known as muscle-sparing) reconstruction. The new technique is emerging as a highly popular surgery owing to its more minimal appr...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clbc.2016.11.009
更新日期：2017-07-01 00:00:00
abstract：BACKGROUND:The diagnosis of breast cancer in young women (aged 18-45 years) has been increasing. Women are commonly left coping with treatment-related disabilities of the upper limb that can persist for > 2 years postoperatively. PATIENTS AND METHODS:A total of 59 young breast cancer patients (29 in the intervention g...
journal_title：Clinical breast cancer
pub_type： 杂志文章,随机对照试验
doi：10.1016/j.clbc.2017.06.007
更新日期：2018-02-01 00:00:00
abstract：:The potential for cardiac toxicity in association with targeted biologic agents was first observed with trastuzumab, a monoclonal antibody that targets the ErbB2/HER2 receptor. In the pivotal trial of trastuzumab in ErbB2-positive metastatic cancer, an increased incidence of serious cardiac events was observed, partic...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/cbc.2008.s.007
更新日期：2008-03-01 00:00:00
abstract：BACKGROUND:The adoption of hypofractionated radiotherapy (HFRT) into clinical practice varies widely despite randomized trials and guidelines supporting its equivalence to conventional fractionated radiotherapy (CFRT) for certain patient populations. We assessed the use of HFRT at a single institution from 2011 to 2018...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2020.03.006
更新日期：2020-10-01 00:00:00
abstract：PURPOSE:We investigated the efficacy and toxicity of sorafenib, a multikinase inhibitor of vascular endothelial growth factor receptor tyrosine kinase, in combination with vinorelbine therapy in a phase I/II trial in patients with metastatic breast cancer. PATIENTS AND METHODS:We enrolled 11 patients in the phase I po...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2013.10.013
更新日期：2014-04-01 00:00:00
abstract：BACKGROUND:Recent studies have shown that breast cancer detected by screening has a more favorable prognosis than interval breast cancer. To further understand the biologic significance of this finding, we investigated the association of disease recurrence, local and distant, with the method of detection of the primary...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/CBC.2008.n.014
更新日期：2008-04-01 00:00:00
abstract：BACKGROUND:We examined tumor genotype characteristics of human epidermal growth factor receptor 2 (HER2)-positive relapsed (R-) and de novo (dn-) metastatic breast cancer (MBC) in trastuzumab-treated patients who were previously not exposed to this agent. MATERIALS AND METHODS:We analyzed genotypes obtained upon deep ...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2018.10.014
更新日期：2019-04-01 00:00:00
abstract：INTRODUCTION:The purpose of this study was to evaluate whether diagnostic performance of breast magnetic resonance imaging (MRI) for detection of multifocality and multicentricity (MFMC) of breast cancer (BC) can be influenced by different histotypes or immunophenotypes in newly diagnosed patients with breast cancer. ...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2017.10.012
更新日期：2018-04-01 00:00:00
abstract：BACKGROUND:This study was performed to determine whether the use of ovulation induction drugs in treatment of infertility have a significant effect on the risk of breast cancer. PATIENTS AND METHODS:This case control study (928 cases, 928 controls), was performed in the gynecology and oncology clinics of Shahid Behesh...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2018.03.003
更新日期：2018-10-01 00:00:00
abstract：AIM:Our study was to investigate the heterogeneity of estrogen receptor (ER) expression among tumor sites by using fluorine-18 ((18)F) fluoroestradiol (FES) positron-emission tomography-computed tomography (PET-CT) imaging. METHODS:Thirty-two breast cancer patients underwent both (18)F-FES and (18)F fluorodeoxyglucose...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2013.02.012
更新日期：2013-10-01 00:00:00
abstract：PURPOSE:To determine the overall performance of contrast-enhanced ultrasound (CEUS) in differentiating between benign and malignant breast lesions and in predicting the pathologic response to neoadjuvant chemotherapy (NAC) in patients with breast cancer (BC). MATERIALS AND METHODS:Articles published up to April 2019 w...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2020.03.002
更新日期：2020-08-01 00:00:00
abstract：:This article attempts to provide the reader with a complete overview of topoisomerase (topo) II alpha as a marker for predicting the efficacy of anthracyclines in patients with breast cancer. In the first section of this article, in vitro data supporting the predictive value of topo II alpha are reviewed. Interestingl...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：
更新日期：2003-08-01 00:00:00
abstract：BACKGROUND:Postmenopausal women with hormone receptor-positive (HR(+)) breast cancer in whom disease progresses or there is recurrence while taking a nonsteroidal aromatase inhibitor (NSAI) are usually treated with exemestane (EXE), but no single standard of care exists in this setting. The BOLERO-2 trial demonstrated ...
journal_title：Clinical breast cancer
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.1016/j.clbc.2013.08.011
更新日期：2013-12-01 00:00:00
abstract：BACKGROUND:The study aimed to evaluate the feasibility and reliability of ultrasound-guided vacuum-assisted breast biopsy (US-VABB) for sampling of microcalcifications indicative of cancer when stereotactic vacuum-assisted breast biopsy cannot be performed because of reasons such as thin breast tissue, insufficient thi...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2018.12.002
更新日期：2019-04-01 00:00:00
abstract：:The development of third-generation aromatase inhibitors (AIs) has brought about a major change in the therapeutic approach to patients with hormone-sensitive breast cancer. In randomized clinical trials, each of the third-generation AIs has demonstrated efficacy in the adjuvant treatment of postmenopausal women with ...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/CBC.2005.n.022
更新日期：2005-08-01 00:00:00
abstract：BACKGROUND:Three-drug regimens containing gemcitabine, an anthracycline, and a taxane produce response rates of 70%-90% in patients with metastatic breast cancer (MBC) although accompanied by considerable hematologic toxicity. We explored the combination of gemcitabine/epirubicin/docetaxel as neoadjuvant therapy. Docet...
journal_title：Clinical breast cancer
pub_type： 杂志文章,多中心研究
doi：10.3816/CBC.2010.n.029
更新日期：2010-06-01 00:00:00
abstract：INTRODUCTION:This study evaluated the association between aromatase inhibitor (AI) therapy and cognitive function (over a 6-month period) in a cohort of patients aged ≥ 60 years compared with an age-matched healthy control group, and it evaluated changes in regional cerebral metabolism as measured by positron emission ...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2013.10.010
更新日期：2014-04-01 00:00:00
abstract：:Involvement of axillary lymph nodes is an important prognostic factor in relationship to the management of breast cancer. However, the use of neoadjuvant systemic therapy is widespread in the treatment of positive axilla and such treatment leads to downstaging of axillary disease. Hence, the role of targeted axillary ...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2018.06.001
更新日期：2018-10-01 00:00:00
abstract：:Chyle fistula is not a well-known complication of axillary dissection in patients with breast cancer. Although rare, this complication can occur as a result of anatomic variation of the thoracic duct and its venous anastomosis. Injury to the lateral terminating branches or lymphatic trunk, leading to retrograde chyle ...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/CBC.2006.n.030
更新日期：2006-06-01 00:00:00
abstract：BACKGROUND:Although magnetic resonance imaging (MRI) is a useful imaging modality for invasive cancer, its role in preoperative surgical planning for ductal carcinoma in situ (DCIS) has not been established. We sought to determine whether preoperative MRI affects surgical treatment and outcomes in women with pure DCIS....
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/CBC.2011.n.006
更新日期：2011-03-01 00:00:00
abstract：PURPOSE:This multicenter phase II trial evaluated the efficacy and safety of weekly nanoparticle albumin-bound paclitaxel with carboplatin and weekly trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer (MBC). PATIENTS AND METHODS:We treated 32 patients who had measurable MBC t...
journal_title：Clinical breast cancer
pub_type： 杂志文章,多中心研究
doi：10.3816/CBC.2010.n.036
更新日期：2010-08-01 00:00:00
abstract：:Despite the widespread use of trastuzumab in the management of patients with HER2-overexpressing metastatic breast cancer, its optimal duration of administration is unknown. We retrospectively reviewed the medical records of 80 such patients who received trastuzumab monotherapy or combination chemotherapy beyond disea...
journal_title：Clinical breast cancer
pub_type： 杂志文章,多中心研究
doi：10.3816/cbc.2003.n.017
更新日期：2003-06-01 00:00:00
abstract：:Breast carcinoma in men is rare and comprises approximately 1% of all breast cancer cases. In contrast to the increase in the detection rate of ductal carcinoma in situ (DCIS) in women resulting from the wide use of screening mammography programs, the rate of male DCIS is still small and represents approximately 5% of...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/CBC.2005.n.033
更新日期：2005-10-01 00:00:00
abstract：BACKGROUND:Single-frequency bioelectrical impedance (BI) has been used to measure extracellular fluid in the upper limbs. The purpose of the study was to evaluate BI's ability to detect and monitor upper limb changes in based upon the extent of various treatments and to assess its practicality. METHODS:Patients with n...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2012.01.004
更新日期：2012-04-01 00:00:00
abstract：BACKGROUND:Most investigations have compared triple-negative breast cancer (TNBC) to non-TNBC to elucidate clinical or epidemiologic differences between subtypes. We examined a contemporary cohort of patients with primary TNBC by detection and age at diagnosis within a population-based breast screening program to exami...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2018.04.013
更新日期：2018-10-01 00:00:00
abstract：BACKGROUND:Disrupting the autophagic balance to trigger autophagic death may open new strategies for cancer therapy. Transcription factor EB (TFEB) is a master regulator of lysosomal biogenesis and may play a role in cancer biology and clinical behavior. METHODS:The expression of TFEB and the lysosomal cancer cell con...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2016.11.006
更新日期：2017-06-01 00:00:00
abstract：INTRODUCTION:Unwanted clinical variation is common across the United States health care system and is particularly vexing in oncology owing to the complexity, morbidity, and high cost of the disease. Efforts to standardize care including guidelines and continuing medical education have had only limited impact. Disease-...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2018.12.010
更新日期：2019-04-01 00:00:00
